Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA)

Historical Holders from Q2 2021 to Q3 2025

Symbol
CNTA on Nasdaq
CUSIP
152309100
Type / Class
Equity / Ordinary shares, par value 0.002 GBP per share
Shares outstanding
147M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
128M
Holdings value
$3.11B
% of all portfolios
0.009%
Grand Portfolio weight change
+0%
Number of holders
124
Number of buys
57
Number of sells
-69
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 8.06% $262M 10.8M Avoro Capital Advisors LLC Sep 30, 2025
Adage Capital Management, L.P. 7.48% +19.8% $243M $39.6M 10M +19.4% Adage Capital Management, L.P. Sep 30, 2025
General Atlantic Cooperatief U.A. 5% -22.9% $180M -$56.6M 7.37M -23.9% General Atlantic Cooperatief U.A. Nov 25, 2025
FMR LLC 7% $152M 6.28M FMR LLC Sep 30, 2025

Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 128M $3.11B +$148M $24.25 124
2025 Q2 124M $1.62B -$30.7M $13.14 117
2025 Q1 125M $1.8B -$6.44M $14.38 130
2024 Q4 124M $2.08B +$72.9M $16.75 114
2024 Q3 109M $1.74B +$316M $15.99 101
2024 Q2 86.5M $781M +$28.1M $9.03 79
2024 Q1 5.3M $59.8M -$40.6M $11.30 6
2023 Q4 14.3K $114K +$114K $7.96 1
2023 Q3 72.6M $470M +$14.5M $6.47 47
2023 Q2 70.3M $435M +$25.4M $6.19 42
2023 Q1 66.9M $258M +$13.1M $3.85 42
2022 Q4 62.7M $194M +$5.92M $3.10 40
2022 Q3 71.8M $289M -$809K $4.02 41
2022 Q2 71.8M $350M -$37.5M $4.87 37
2022 Q1 74.5M $669M +$23.5M $8.97 39
2021 Q4 71.9M $808M +$18.6M $11.26 45
2021 Q3 56.9M $882M +$147M $16.70 39
2021 Q2 47.4M $1.05B +$1.05B $22.21 48